ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bristol-Myers Squibb and Amgen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Bristol-Myers SquibbAmgen
studies on the registry2,1841,088
open to participants now15550
phase 3 studies under way8250
reach primary completion within a year6735
programswith a study of their own in two years57+9 named only24

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBristol-Myers SquibbAmgen
Phase 1

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%
Phase 2

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%
Phase 3

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%
Approved, new studies

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 5

Where they overlap

Conditions where at least two of them have programs: 21 in all. A program counts in each condition its studies name most.

ConditionBristol-Myers SquibbAmgen
Carcinoma, Non-Small-Cell Lungboth · compare here

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinomaboth · compare here

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

Neoplasmsboth · compare here

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

Colorectal Neoplasmsboth · compare here

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

Lymphoma, Non-Hodgkinboth · compare here

Bristol-Myers Squibb in Lymphoma, Non-Hodgkin: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Non-Hodgkin in search

Amgen in Lymphoma, Non-Hodgkin: 2 programs

  1. afliberceptphase 3
  2. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, Non-Hodgkin in search

Prostatic Neoplasmsboth · compare here

Bristol-Myers Squibb in Prostatic Neoplasms: 3 programs

  1. dezandrodegphase 3
  2. RYZ711phase 2
  3. orevandrodegphase 1

Their studies: Bristol-Myers Squibb’s studies of Prostatic Neoplasms in search

Amgen in Prostatic Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. xaluritamigphase 3

Their studies: Amgen’s studies of Prostatic Neoplasms in search

Arthritis, Rheumatoidboth · compare here

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

Amgen in Arthritis, Rheumatoid: 1 program

  1. dazodalibepphase 3

Their studies: Amgen’s studies of Arthritis, Rheumatoid in search

Lupus Erythematosus, Systemicboth · compare here

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

Amgen in Lupus Erythematosus, Systemic: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Bristol-Myers Squibb in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Large B-Cell, Diffuse in search

Amgen in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, Large B-Cell, Diffuse in search

Neoplasm Metastasisboth · compare here

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

Amgen in Neoplasm Metastasis: 1 program

  1. WRN Inhibitor AMG 436phase 1

Their studies: Amgen’s studies of Neoplasm Metastasis in search

Arthritis, Juvenileboth · compare here

Bristol-Myers Squibb in Arthritis, Juvenile: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Juvenile in search

Amgen in Arthritis, Juvenile: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Arthritis, Juvenile in search

Arthritis, Psoriaticboth · compare here

Bristol-Myers Squibb in Arthritis, Psoriatic: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Psoriatic in search

Amgen in Arthritis, Psoriatic: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Arthritis, Psoriatic in search

COVID-19both · compare here

Bristol-Myers Squibb in COVID-19: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of COVID-19 in search

Amgen in COVID-19: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of COVID-19 in search

Immunoglobulin G4-Related Diseaseboth · compare here

Bristol-Myers Squibb in Immunoglobulin G4-Related Disease: 1 program

  1. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Immunoglobulin G4-Related Disease in search

Amgen in Immunoglobulin G4-Related Disease: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Immunoglobulin G4-Related Disease in search

Liver Diseasesboth · compare here

Bristol-Myers Squibb in Liver Diseases: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Liver Diseases in search

Amgen in Liver Diseases: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Liver Diseases in search

Lymphoma, B-Cellboth · compare here

Bristol-Myers Squibb in Lymphoma, B-Cell: 1 program

  1. golcadomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, B-Cell in search

Amgen in Lymphoma, B-Cell: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, B-Cell in search

Nasopharyngeal Carcinomaboth · compare here

Bristol-Myers Squibb in Nasopharyngeal Carcinoma: 1 program

  1. izalontamab brengitecanphase 3

Their studies: Bristol-Myers Squibb’s studies of Nasopharyngeal Carcinoma in search

Amgen in Nasopharyngeal Carcinoma: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Nasopharyngeal Carcinoma in search

Obesityboth · compare here

Bristol-Myers Squibb in Obesity: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Obesity in search

Amgen in Obesity: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Obesity in search

Pancreatic Neoplasmsboth · compare here

Bristol-Myers Squibb in Pancreatic Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Pancreatic Neoplasms in search

Amgen in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Pancreatic Neoplasms in search

Precursor Cell Lymphoblastic Leukemia-Lymphomaboth · compare here

Bristol-Myers Squibb in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Amgen in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Psoriasisboth · compare here

Bristol-Myers Squibb in Psoriasis: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Psoriasis in search

Amgen in Psoriasis: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Psoriasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Bristol-Myers Squibb 32 of 57 · Amgen 17 of 24 programs (31 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9).